TheraRadar
Clinical-Stage Companies / Cassava Sciences

Cassava Sciences

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 6/26/2024

9
Total Trials
3
Phase 3
3
Phase 2
0
Recruiting
78
Score

Pipeline by Phase

Phase 3
3
Phase 2
3
Phase 1
3

Therapeutic Focus

Alzheimer Disease Alzheimer's Disease Absorption Metabolism Excretion

Clinical Trials (9)

NCT05026177 Phase 3 TERMINATED

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Started: 11/18/2021

NCT04994483 Phase 3 COMPLETED

Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

Started: 11/3/2021

NCT05575076 Phase 3 TERMINATED

Open-label Extension for Phase 3 Clinical Trials of Simufilam

Started: 11/7/2022

NCT05352763 Phase 2 TERMINATED

Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

Started: 5/12/2022

NCT04388254 Phase 2 COMPLETED

Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients

Started: 3/24/2020

NCT04079803 Phase 2 COMPLETED

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Started: 9/9/2019

NCT06195319 Phase 1 COMPLETED

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects

Started: 2/7/2024

NCT06390410 Phase 1 COMPLETED

A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function

Started: 6/26/2024

NCT04932655 Phase 1 COMPLETED

Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers

Started: 5/4/2021

Drug Candidates

Simufilam Placebo simufilam Simufilam 100 mg oral tablet Placebo oral tablet Simufilam 100 mg tablet Simufilam 50 mg oral tablet
Activity Status: Slowing
Last Trial Started: 6/26/2024
Last Trial Ended: 1/31/2025
Trials (12 months): 0
Completed Trials: 6
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.